Seres Therapeutics (MCRB) awards 7,500 stock options to company officer Marella Thorell
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Seres Therapeutics, Inc. reported that company officer Marella Thorell received a compensatory grant of stock options covering 7,500 shares of common stock at an exercise price of $9.13 per share. The options were awarded at no cost and will vest as to 25% of the shares on March 2, 2027, with the remaining shares vesting in 12 equal quarterly installments thereafter, subject to continued service.
Positive
- None.
Negative
- None.
Insights
Routine stock option grant to a Seres Therapeutics officer as part of compensation.
Seres Therapeutics granted Marella Thorell stock options for 7,500 shares of common stock at an exercise price of $9.13 per share. The grant was recorded as an acquisition under a compensation-related award, not an open-market purchase.
The options vest over time: 25% of the shares on March 2, 2027, with the balance vesting in 12 equal quarterly installments thereafter. This long vesting schedule ties a portion of the officer’s potential upside to ongoing service and future company performance, which is typical for equity incentives.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Thorell Marella
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 7,500 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 7,500 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 7,500 shares
Exercise price: $9.13 per share
Post-transaction derivative holdings: 7,500 options
+3 more
6 metrics
Options granted
7,500 shares
Stock options on common stock granted to Marella Thorell
Exercise price
$9.13 per share
Conversion or exercise price of the granted stock options
Post-transaction derivative holdings
7,500 options
Total derivative securities beneficially owned after the transaction
Vesting cliff
25% on March 2, 2027
Initial vesting tranche of the stock option award
Remaining vesting schedule
12 equal quarterly installments
Vesting pattern for remaining option shares after March 2, 2027
Option expiration
March 3, 2036
Expiration date of the stock option award
Key Terms
stock option, exercise price, vesting, derivative securities
4 terms
stock option financial
"The option will vest as to 25% of the shares on March 2, 2027."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "9.1300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option will vest as to 25% of the shares on March 2, 2027."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative securities financial
"total_shares_following_transaction": "7500.0000""
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
What did Marella Thorell report on the Form 4 for Seres Therapeutics (MCRB)?
Marella Thorell reported a grant of stock options for 7,500 shares of Seres Therapeutics common stock at an exercise price of $9.13 per share, received as equity compensation rather than an open-market purchase.
How many Seres Therapeutics (MCRB) options did Marella Thorell receive and at what price?
Marella Thorell received stock options on 7,500 shares of Seres Therapeutics common stock with an exercise price of $9.13 per share, according to the Form 4.
When do Marella Thorell’s Seres Therapeutics (MCRB) options vest?
The options will vest as to 25% of the shares on March 2, 2027. The remaining shares vest in 12 equal quarterly installments thereafter, contingent on continued service.
Is Marella Thorell’s Seres Therapeutics (MCRB) Form 4 a market purchase or a grant?
The Form 4 reflects a grant or award acquisition of stock options, not a market purchase. The transaction is coded as an A (grant, award, or other acquisition) with an exercise price of $9.13 per share.
How many Seres Therapeutics (MCRB) derivative securities does Marella Thorell hold after this transaction?
Following this grant, Marella Thorell holds 7,500 stock options related to Seres Therapeutics common stock, as indicated by the total derivative securities beneficially owned after the reported transaction.